Skip to main content
A

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,284 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物2025年年度股东会会议材料
Regulatory Filings
2026-05-07 Chinese
安图生物关于使用闲置募集资金进行现金管理赎回的公告
Regulatory Filings
2026-05-07 Chinese
安图生物2025年年度利润分配预案公告
Notice of Dividend Amount Classification · 1% confidence The document is an announcement of the company's proposed 2025 profit distribution (dividend) plan, specifying per-share cash dividend amount, total dividend amount, record date mechanics, and related approval process. This corresponds precisely to a “Notice of Dividend Amount” (DIV).
2026-04-22 Chinese
安图生物第五届董事会第十一次会议决议公告
Board/Management Information Classification · 1% confidence The document is a formal announcement of the Company’s Board of Directors meeting resolutions (the 11th meeting of the 5th Board), listing agenda items considered and voting results. It does not present a financial report itself nor announce an AGM or dividend. It is a Board/Management Information announcement.
2026-04-22 Chinese
安图生物2026年第一季度报告
Interim / Quarterly Report Classification · 1% confidence The document is titled '郑州安图生物工程股份有限公司2026年第一季度报告' (Zhengzhou Autobio Diagnostics Co., Ltd. 2026 First Quarter Report). It contains comprehensive financial statements including the balance sheet, income statement, and cash flow statement for the first quarter of 2026. It is a full quarterly report, not an announcement or summary, and meets the criteria for an Interim/Quarterly Report (IR). Q1 2026
2026-04-22 Chinese
安图生物关于2026年度“提质增效重回报”行动方案的公告
Regulatory Filings Classification · 1% confidence The document is a corporate announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding its 2026 “quality improvement and return” action plan in response to a Shanghai Stock Exchange initiative. It outlines strategic and operational measures rather than presenting financial results, voting outcomes, governance charters, or management changes. It is not an AGM presentation, earnings release, annual or interim report, or any other specific category. Therefore, it falls under a general regulatory announcement that does not fit other specific filing types: Regulatory Filings (RNS).
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.